A Randomized, Double Blinded, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of anti-SARS-CoV-2 Convalescent Plasma in Hospitalized Patients (CONTAIN COVID-19)

<p>This dataset contains de-identified patient data of 941 patients from 21 centers across the United States who were&nbsp;enrolled in the CONTAIN COVID-19 randomized controlled trial&nbsp;that ran from 4/17/2020-3/15/2021.&nbsp; The information in this dataset was used to conduct the analysis reported in the CONTAIN COVID-19 manuscript published in JAMA Internal Medicine (doi: 10.1001/jamainternmed.2021.6850)&nbsp;&nbsp;and includes demographic information, baseline history, baseline medications, baseline laboratory values, clinical status based on the WHO 11-point scale at 14 and 28 days after randomization, antibody titers, randomization arms.</p>